49results about "Micromachined delivery" patented technology

An embodiment relates to an active implantable medical device (AIMD), comprising: a permeability module that allows ingress flow of a fluid to an osmotic agent chamber and generates osmotic pressure; a piston that moves longitudinally within the active implantable medical device (AIMD) in response to the osmotic pressure; a drug chamber that comprises a drug and a valve module to allow one-way flow of the drug from the drug chamber to outside the active implantable medical device (AIMD); a sensor module that measures a displacement of the piston in real-time; and an electronic module that communicates a signal to the valve module to control the valve module and regulate the one-way flow of the drug based on the displacement of the piston.

The invention relates to a graphene hydrogel neural microelectrode and a preparation method thereof.The neural microelectrode comprises a long-strip-shaped electrode body, the electrode body comprises an insulating substrate layer, a conductive layer and an insulating covering layer, and the conductive layer is wrapped and sealed by the insulating substrate layer and the insulating covering layer; a contact window is arranged at one end, close to the electrode body, of the insulating covering layer, a conductive expansion layer made of graphene hydrogel is arranged below the contact window and the insulating covering layer on the periphery of the contact window, the conductive expansion layer is electrically connected with the conductive layer, and the conductive expansion layer can expand after being heated or absorbing water to form an electrode contact protruding outwards from the contact window. Amino multi-walled carbon nanotubes, amino graphene quantum dots and gold nanoparticles are loaded in the graphene hydrogel. The electrode contact has the advantages that after the electrode contact is heated or absorbs water, the conductive expansion layer expands to form the electrode contact protruding out of the contact window, and the electrode contact is good in tissue affinity, capable of making better contact with nervous tissue and more excellent in performance.

A system for targeted delivery of a medicament to the gastrointestinal tract (e.g., selectively to the duodenum) of a subject. The system includes a medicament, a mucoadhesive layer at least partially surrounding the medicament, and an enteric coating encasing the medicament and mucoadhesive layer. The enteric coating comprises a material degradable by a pH of the GI tract and a material digestible by a lipase. Also provided are method of making and using the system for targeted delivery of a medicament to the gastrointestinal tract. Also provided are a system for deploying a medicament-containing needle system using an expanding element. The system includes a medicament-containing needle system and an expanding element within a capsule. The capsule is initially coated with an enteric coating. As the enteric coating degrades the expanding element absorbs fluid that enters the capsule and expands to deploy the medicament-containing needle system from the capsule.

An embodiment relates to a system comprising a fluid chamber containing a fluid; an Active Wearable Medical Device (AWMD) comprising a permeability module configured to allow ingress of fluid from the fluid chamber to an osmotic agent chamber via a semi-permeable membrane to generate osmotic pressure; a piston that moves longitudinally in response to the osmotic pressure; a drug chamber comprising a drug and a valve module configured to enable one-way drug flow from the chamber to outside the AWMD; a sensor module to measure piston displacement and provide real-time data; and an electronic module configured to regulate drug ejection based on the displacement data, ensuring dose-to-dose volume variation remains within ±25%. A machine learning model triggers alerts if dosing deviates from threshold limits. A channel is fluidically coupled to the AWMD and delivers the drug to the subject. The AWMD is externally worn and not implanted.

The present disclosure provides a drug delivery device. The drug delivery device is orally ingested by a patient and then actuated within the patient's gastrointestinal (GI) tract. Upon actuation, the arms of the drug delivery device extend, causing the piercing tip to penetrate the GI tract wall. A driver then drives a plunger within the drug delivery device, pushing the drug through the piercing tip and the patient's GI tract wall. After a period of time, a portion of the drug delivery device dissolves, allowing the drug delivery device to pass through the GI tract.

Drug delivery devices and methods of controlled drug delivery to a patient are provided. The drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.

The present invention provides drug delivery devices and methods for controlled drug delivery to a patient. The drug delivery devices can include one or two microchip elements, each having a body portion with one or more drug release apertures in fluid communication with at least one contained reservoir. The drug release apertures are closed by one or more reservoir covers that can be electrically activated to open the drug release apertures. The drug delivery devices further include (i) a drug formulation disposed in the at least one contained reservoir, and (ii) at least one drug permeable membrane. In some cases, an outer housing is spaced apart from an outer wall of the body portion of the microchip element, the outer housing includes the at least one drug permeable membrane, and defines a reservoir space between the drug permeable membrane and the outer wall of the body portion of the microchip element.

The object of the invention is a method for obtaining an injectable biocompatible drug delivery vehicle, cell carrier or combinations thereof, in the form of microscaffolds, characterised in that it comprises the following steps: a) preparation of a solution containing a polymer and at least one solvent; b) formation of fibres with a diameter of 50 nm to 10 pm on a flat collector by electrospinning; c) laser cutting of the nonwoven fabric formed on the collector into individual separate scaffold microscaffolds with a thickness of 0.01 to 0.2 mm and either a cylinder-form with a base diameter of 0.1 to 0.4 mm or a prism-form with a base edge length of 0.04 to 0.4 mm; d) separation of the microscaffolds from the collector; e) chemical modification of the microscaffolds by suspending them in an aqueous NaOH solution of 0.001-1 M concentration for 1-120 min or physical modification by suspending them in an aqueous protein solution of 0.001-0.5 M concentration for 2-120 min; f) removing excess NaOH or protein from the surface of the microscaffolds. A further object of the invention is an injectable delivery composition comprising a buffer and biocompatible in vitro mutually non-aggregating drug vehicles, cell carriers, or combinations thereof, characterised in that the vehicles / carriers are electrospun fibre microscaffolds fabricated with the method according to the invention, wherein each microscaffold is a single vehicle / carrier with a thickness of 0.005 to 0.2 mm and the shape of a cylinder with a base diameter of 0.05 to 0.5 mm or a prism with a base edge length of 0.05 to 0.5 mm, the surface of which is modified chemically with NaOH solution or physically with a protein solution, whereby the microscaffolds suspended in the buffer form a suspension of non-aggregating microparticles. Another object of the invention is the use of the composition according to the invention in the treatment of bone, cartilage, and intervertebral disc injuries.

To provide drug delivery devices and methods of controlled drug delivery to a patient.SOLUTION: A drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.SELECTED DRAWING: Figure 2

The present disclosure provides a drug delivery device. The drug delivery device is taken orally by a patient, and then activates within the gastrointestinal (GI) tract of the patient. Upon activation, arms of the drug delivery device expand, and penetrating tips penetrate the GI tract walls. A driver then drives a plunger within the drug delivery device, pushing a drug through the penetrating tips and through the GI tract walls of the patient. After a period of time, part of the drug delivery device dissolves and the drug delivery device passes through the GI tract.

Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and / or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and / or degraded within the GI tract.

Embodiments of the present invention are directed to a liquid delivery apparatus. A non-limiting example of the apparatus includes a substrate including a cavity formed in a surface of the substrate. The apparatus can also include a membrane disposed on the surface of the substrate covering an opening of the cavity. The apparatus can also include a hydrophobic layer disposed on the membrane. The apparatus can also include a seal disposed between the membrane and the substrate, wherein the seal surrounds the opening of the cavity. The apparatus can also include an electrode layer coupled to the membrane.

The present disclosure provides a drug delivery device. The drug delivery device is orally ingested by a patient and then activated within the patient's gastrointestinal (GI) tract. Upon activation, a resilient arm within the drug delivery device expands and engages the GI tract wall. A driver then drives a plunger within the drug delivery device, pushing a drug through a channel in the resilient arm and through the patient's GI tract wall. After a period of time, at least a portion of the drug delivery device dissolves, and the drug delivery device passes through the GI tract.

A method for identifying the presence or progression of hypoxic ischemic brain injury includes, for each subset of one or more subsets of a three-dimensional medical image of a head of a patient: (i) inputting said each subset into a machine-learning model, (ii) extracting one or more features or feature maps from the machine-learning model, and (iii) constructing, based on the one or more features or feature maps, one of a sequence of vectors. The sequence of vectors is then pooled to obtain a scan-level vector that is used to obtain a score indicating HIBI presence or progression in the patient. For example, the scan-level vector can be inputted into a pre-trained classifier that generates the score based on the scan-level vector. The machine-learning model may be a pre-trained conventional neural network or support vector machine.

The present disclosure provides a drug delivery device. The drug delivery device is orally ingested by a patient and then activated within the patient's gastrointestinal (GI) tract. Upon activation, a resilient arm within the drug delivery device expands and engages the GI tract wall. A driver then drives a plunger within the drug delivery device, pushing a drug through a channel in the resilient arm and through the patient's GI tract wall. After a period of time, at least a portion of the drug delivery device dissolves, and the drug delivery device passes through the GI tract.

To provide drug delivery devices and methods of controlled drug delivery to a patient.SOLUTION: A drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.SELECTED DRAWING: Figure 2

A scalable method of continuous microfluidic synthesis of tannic acid-iron III (TA-FeIII) network (TFN) nanocapsules of a hydrophobic drug; a scalable method of continuous microfluidic synthesis of epigallocatechin-3-gallate iron III (EGCG-FeIII) network, (EFN) nanocapsules; hydrophobic drug nanocapsules synthesized in accordance with the method; and a method of administering a hydrophobic drug to a patient in need thereof by administering to the patient the hydrophobic drug nanocapsules.

An active drug dispensing ophthalmic device can include a plurality of drug reservoirs, each covered by an electrode, and a controller-responder architecture. Electrodissolution of each electrode and the associated drug release can be governed by a controller via a responder. Employing a controller-responder architecture can reduce the number of connections and separate electrical signals required to actively dispense drugs from each of the plurality of drug reservoirs. The controller can be connected to a plurality of responders via a control line bundle and each of the plurality of responders can deliver signals to the electrode(s) covering a portion of a plurality of drug reservoirs. The controller-responder architecture can also employ a composite electrical communication signal to even further decrease the number of electrical connections required from a controller to each of the responders.

A hollow body has a bottom, an upper end wall, and side walls extending between the bottom and the upper end wall. The upper end wall and side walls are made of metal. The cavity within the hollow body has a volume in the range between 1 picoliter to 1,000 picoliter. The upper end wall comprises at least one opening. The hollow body is suitable for encapsulating small amounts of liquid, or a small micro-electromechanical system, and may be used for the controlled release of pharmaceutical components.

The present disclosure relates to a method of treating a gastrointestinal (GI) inflammatory disease or condition in a subject in need thereof, comprising topically administering to the subject a pharmaceutical formulation comprising a therapeutically effective amount of a JAK inhibitor, said topical administration comprising orally administering an ingestible device to the subject, said device containing the pharmaceutical formulation, and releasing the pharmaceutical formulation from the device (a) to a section or subsection of the subject's GI tract containing one or more inflammatory disease sites; or (b) proximal to a section or subsection of the subject's GI tract containing one or more inflammatory disease sites, wherein the onset of the pharmaceutical formulation release occurs before the ingestible device reaches the disease site.

Describes a device that is on the order of μm or nm in size and can include integrated circuit logic, a sensing subsystem, a decision-making subsystem, an implementation subsystem, and a power harvesting system based on sub-10nm SIA transistor nodes. The sensing subsystem can identify pathogenic entities, which include disease-related cells (such as cancer cells, autoimmune cells, or pathogenic microorganisms) or viruses. The sensing subsystem can include at least one pad made of a conductive material and at least one linker attached to the at least one pad. Each linker can also be attached to a targeting agent (such as an antibody fragment) or a reference agent. After the targeting agent binds to the entity of interest, information is transmitted to the logic circuit, which processes the binding event information and determines whether the entity is disease-related (e.g., a disease-related cell or virus) and requires the delivery of a therapeutic agent or other treatment.

Described herein are unit cells including a base plate; a top plate; and a lumen extending longitudinally from the base plate to the top plate, the lumen defined by a side wall formed from a plurality of cojoined panels extending between a bottom surface of the top plate and a top surface of the base plate. The unit cell can be magnetically actuatable, such that the unit cell can be reversibly transitioned between a contracted configuration, an extended configuration, or a combination thereof using an applied magnetic field.

The invention belongs to the technical field of biological medicine, and particularly relates to a noninvasive controllable flexible biological electronic patch for treating diabetic erectile dysfunction. The erectile dysfunction related to diabetes is difficult to recover due to long-term damage of a cavernous body microenvironment, traditional oral administration or cavernous body injection treatment has poor targeting, non-uniform distribution and complication risk, and long-term curative effect is difficult to realize. The invention provides a flexible and attachable bioelectronic patch which is used for noninvasively, painlessly and controllably adjusting an erectile tissue microenvironment. The device synergistically promotes local vascular active factor expression and endothelial repair through mild electrical stimulation, realizes uniform transdermal delivery of drug molecules, shows high delivery efficiency and cell activity, and significantly improves cavernous body blood flow and cell functions. In an in-vitro cell model and a diabetic animal model, the device shows better vascular regeneration and function recovery effects than traditional medicine or injection therapy.

To provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract.SOLUTION: Many embodiments provide a swallowable device, e.g., a capsule for delivering TAs into an intestinal wall (IW). Embodiments also provide TA preparations configured to be contained in the capsule and advanced from the capsule into the IW and / or a surrounding tissue (ST) and degrade to release the TA into a bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration in which the preparation is contained in the capsule, and a second configuration in which the preparation is advanced out of the capsule into the IW or ST (e.g., a peritoneal cavity). Embodiments are particularly useful for delivery of such CFs for treatment of clotting disorders (e.g., hemophilia) where the CFs are poorly absorbed and / or degraded within a GI tract.SELECTED DRAWING: Figure 11-3

Device (1) for the passive release of a substance into a solution, said device allowing the tracking of the release by means of intra body communication, and comprising a transmitter (2) configured to generate an alternating electrical signal, powered by a battery and provided with a first electrode (3) and with a second electrode (4); a passive release component (5) made of electrically insulating material and comprising said substance, the passive release component (5) degradable in the environment of interest allows the release of said substance, said material (5) incorporates the electrode (3); a stable, electrically conductive, component (6), not degradable in the solution for the release into which the second electrode (4) is incorporated.

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a PDE4 inhibitor.

Provided is a micro- and nano-fluidic chip, including at least one nanochannel array layer and at least one microchannel array layer that are alternately stacked. The at least one nanochannel array layer includes nanochannels, the at least one microchannel array layer includes input units and / or output units. The input unit includes inlet microchannel arrays and inlets, and the output unit includes outlet microchannel arrays and outlets. The inlet microchannel array includes inlet microchannels, the outlet microchannel array includes outlet microchannels, and the inlet microchannels and the outlet microchannels are connected through the nanochannel. In this micro- and nano-fluidic chip, the nanochannel can effectively mechanically squeeze biological particles having a membrane structure such as extracellular vesicles (EVs) so as to introduce pores in the membrane of the biological particles such as EVs thereby realizing cargo-loading function, and can also effectively improve the loading efficiency of exogenous cargos, retain the biological viability of the biological particles, and increase the throughput of the cargo-loading process. In addition, a method for fabricating the above-mentioned micro- and nano-fluidic chip and a method for preparing cargo-loading biological particles are also provided.

The present disclosure provides a drug delivery device. The drug delivery device is taken orally by a patient, and then activates within the gastrointestinal (GI) tract of the patient. Upon activation, arms of the drug delivery device expand, and penetrating tips penetrate the GI tract walls. A driver then drives a plunger within the drug delivery device, pushing a drug through the penetrating tips and through the GI tract walls of the patient. After a period of time, part of the drug delivery device dissolves and the drug delivery device passes through the GI tract.

A system for targeted delivery of a medicament to the gastrointestinal tract (e.g., selectively to the duodenum) of a subject. The system includes a medicament, a mucoadhesive layer at least partially surrounding the medicament, and an enteric coating encasing the medicament and mucoadhesive layer. The enteric coating comprises a material degradable by a pH of the GI tract and a material digestible by a lipase. Also provided are method of making and using the system for targeted delivery of a medicament to the gastrointestinal tract. Also provided are a system for deploying a medicament-containing needle system using an expanding element. The system includes a medicament-containing needle system and an expanding element within a capsule. The capsule is initially coated with an enteric coating. As the enteric coating degrades the expanding element absorbs fluid that enters the capsule and expands to deploy the medicament-containing needle system from the capsule.

Device (1) for the passive release of a substance into a solution, said device allowing the tracking of the release by means of intra body communication, and comprising a transmitter (2) configured to generate an alternating electrical signal, powered by a battery and provided with a first electrode (3) and with a second electrode (4); a passive release component (5) made of electrically insulating material and comprising said substance, the passive release component (5) degradable in the environment of interest allows the release of said substance, said material (5) incorporates the electrode (3); a stable, electrically conductive, component (6), not degradable in the solution for the release into which the second electrode (4) is incorporated.